Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報

【英語タイトル】Miragen Therapeutics Inc (MGEN) - Medical Equipment - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7157)・商品コード:DATA904C7157
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:36
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.

Miragen Therapeutics Inc (MGEN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Merger 11
Signal Genetics Merges with miRagen Therapeutics 11
Equity Offering 13
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Acquisition 18
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc – Key Competitors 19
Miragen Therapeutics Inc – Key Employees 20
Miragen Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 22
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 24
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 26
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 28
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 30
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 32
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 34
Corporate Communications 35
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Miragen Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Signal Genetics Merges with miRagen Therapeutics 11
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc, Key Competitors 19
Miragen Therapeutics Inc, Key Employees 20
Miragen Therapeutics Inc, Subsidiaries 21

List of Figures
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★調査レポート[Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報] (コード:DATA904C7157)販売に関する免責事項を必ずご確認ください。
★調査レポート[Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆